Unveiling the power of plumbagin: revitalizing exhausted T cells to combat tongue cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Plumbagin revitalizes exhausted T cells in tongue squamous cell carcinoma (TSCC) by targeting the PD-1 pathway. This study demonstrates plumbagin
Area Of Science
- Immunology
- Oncology
- Pharmacology
Background
- Tongue squamous cell carcinoma (TSCC) is a prevalent oral cancer with a poor prognosis, often linked to T cell exhaustion and immune evasion within the tumor microenvironment (TME).
- While plumbagin exhibits anticancer properties, its role in modulating the TME and overcoming immune escape in TSCC remains unexplored.
- This research investigates plumbagin's immunomodulatory effects to inform neoadjuvant immunotherapy strategies for TSCC.
Purpose Of The Study
- To evaluate the immunomodulatory effects of plumbagin in tongue squamous cell carcinoma (TSCC).
- To determine plumbagin's potential to overcome T cell exhaustion and immune escape in the TSCC tumor microenvironment (TME).
- To provide a theoretical basis for developing plumbagin-based neoadjuvant immunotherapy strategies for TSCC.
Main Methods
- T cells were stimulated to induce exhaustion, characterized by decreased cytotoxic function and increased PD-1 expression.
- Plumbagin's effects on exhausted T cells were assessed in vitro using flow cytometry for apoptosis and PD-1 expression.
- Quantitative reverse transcription PCR measured cytokine expression (Granzyme B, IFN-γ, IL-10, TGF-β).
- In vivo studies utilized plumbagin-treated mouse models (homograft and in situ) to analyze T cell alterations, PD-1 expression, and cytokine profiles via flow cytometry and immunohistochemistry.
Main Results
- Plumbagin enhanced exhausted T cell viability in vitro, promoting apoptosis and reducing PD-1 expression.
- In vivo, plumbagin inhibited TSCC growth, increased the CD8+/CD4+ T cell ratio, and decreased regulatory T cells (Tregs) and PD-1 expression.
- Plumbagin treatment led to significant regulation of cytokine expression within the tumor microenvironment.
Conclusions
- Plumbagin effectively restores exhausted T cell viability through modulation of the PD-L1/PD-1 axis.
- The findings indicate that plumbagin inhibits immune escape in TSCC by revitalizing anti-tumor T cell responses.
- This study provides a strong theoretical foundation for utilizing plumbagin to regulate the immune microenvironment in TSCC treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...